In Focus channel feed – Endpoints News

In Focus channel feed

As fears mount over J&J and AstraZeneca, Novavax enters a shaky spotlight

5 years ago

Nearly a year after Audentes' gene therapy deaths, the trial continues. What happened remains a mystery

5 years ago

'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials

5 years ago

David Liu has a new big idea: proteome editing. It could one day shred tau, RAS and some of the worst disease-causing proteins

5 years ago

Biopharma's success rate in bringing drugs to market has long been abysmal. Can new tools help rewrite that troubled past?

5 years ago

Exclusive: After four decades, one researcher's radical HIV cure finally gets its shot

5 years ago

After 3 deaths rock the field, gene therapy researchers contemplate AAV's future

5 years ago

Can a new CRISPR technique unlock the secrets of how cancer spreads?

5 years ago

They thought their gene therapy failed. Instead, it spawned a medical mystery

5 years ago

As the curtain closes on the Trump presidency, biotech wrestles with its future in a divided America

5 years ago

Can a darkhorse synthetic biology Covid-19 vaccine one-up the frontunners? The Gates Foundation, Amgen bet 'yes'

5 years ago

After falling behind the leaders, dissed by some experts, biotech showman Patrick Soon-Shiong finally gets his Covid-19 vaccine ready for a trial. But can it live up to the hype?

5 years ago

Endpoints News ranks the top 57 players in the Covid-19 vaccine race. Here's how it stacks up today

5 years ago

After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything

5 years ago

After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought

5 years ago

Chinese vaccine developers have begun to shed some secrecy around Covid-19 candidates. What do we know?

5 years ago

Why Merck waited, and what they now bring to the Covid-19 fight

5 years ago

Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology

6 years ago

Banking on hope, swayed by hype? Hydroxychloroquine in the time of Covid-19

6 years ago

Creative or unethical? Researchers’ Covid-19 GoFundMe campaign spurs critics

6 years ago

Natural killers are coming for Covid-19 and the therapy, experts say, could make things worse

6 years ago

‘If grippe condemns, the secondary infections execute’: What the coronavirus pandemic means for the field of antibiotics

6 years ago

Investing in the time of coronavirus: the good, the bad and the hopeful, as biotech VC firms close funds worth $3B

6 years ago

‘It’s like the tortoise and the hare’: A pandemic puts Sanofi’s $600M bet to the test

6 years ago

First page Previous page 4 5 678 Next page Last page